Exelon Corporation Common Stock vs Twist Bioscience Corp — how do they compare? Exelon Corporation Common Stock trades at $41.74 (market cap $42.99B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Exelon Corporation Common Stock is far larger — about 4.3× Twist Bioscience Corp's market cap, and Exelon Corporation Common Stock pays a 4.03% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| EXC | TWST | |
|---|---|---|
Market Cap | $42.99B | $10.08B |
Volume | 7,570,408 | 4,229,037 |
Sector | Utilities | Health |
52-Week High | $50.29 | $205.00 |
52-Week Low | $40.20 | $25.45 |
Enterprise Value | $93.85B | $10.01B |
Dividend Yield | 4.03% | — |
Typical Hold Time | — | 27 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →